Dr. Kantor’s research centers on understanding how modifiable exposures, such as drugs and supplements, relate to cancer risk and survival. She seeks to address these research interests through use of data from a variety of sources, including epidemiologic cohorts, nationally representative surveys, and integrated healthcare delivery systems. Before moving to Memorial Sloan Kettering, Dr. Kantor completed a post-doctoral research fellowship at the Harvard School of Public Health, a PhD in Epidemiology at the University of Washington, and an MPH at the University of Michigan.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Elizabeth Kantor discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.